Ibio Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ibio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ibio.

Ibio is scheduled to release its next quarterly earnings announcement on Friday, September 18th 2020.
View our earnings forecast for Ibio.

Shares of Ibio reverse split on the morning of Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 8th 2018. An investor that had 100 shares of Ibio stock prior to the reverse split would have 10 shares after the split.

1 Wall Street analysts have issued 12-month price targets for Ibio's stock. Their forecasts range from $2.55 to $2.55. On average, they expect Ibio's share price to reach $2.55 in the next year. This suggests a possible upside of 8.5% from the stock's current price.
View analysts' price targets for Ibio.

Ibio saw a increase in short interest in August. As of August 31st, there was short interest totaling 16,020,000 shares, an increase of 119.5% from the August 15th total of 7,300,000 shares. Based on an average trading volume of 33,640,000 shares, the short-interest ratio is presently 0.5 days.
View Ibio's Short Interest.

Some companies that are related to Ibio include NGM Biopharmaceuticals (NGM), Kymera Therapeutics (KYMR), Concordia International (CXR), PureTech Health (PRTC), Oxford BioMedica (OXB), Aptose Biosciences (APS), SIGA Technologies (SIGA), Biotest (BIO), CEL-SCI (CVM), Altimmune (ALT), iShares Diversified Alternatives Trust (ALT), Inventiva (IVA), Pfenex (PFNX), Pfenex (PFNX) and IMV (IMV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ibio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Novavax (NVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

Ibio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Ibio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Jane Street Group LLC (0.27%), Nuveen Asset Management LLC (0.16%), Bank of New York Mellon Corp (0.13%), Charles Schwab Investment Management Inc. (0.12%), Goldman Sachs Group Inc. (0.06%) and New York State Common Retirement Fund (0.05%). Company insiders that own Ibio stock include Eastern Capital Ltd, James P Mullaney and Robert L Erwin.
View institutional ownership trends for Ibio.

IBIO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. Company insiders that have sold Ibio company stock in the last year include Eastern Capital Ltd, James P Mullaney, and Robert L Erwin.
View insider buying and selling activity for Ibio.

IBIO stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Jane Street Group LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, New York State Common Retirement Fund, National Asset Management Inc., Virtu Financial LLC, and Harvey Capital Management Inc..
View insider buying and selling activity for Ibio.

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IBIO stock can currently be purchased for approximately $2.35.

Ibio has a market capitalization of $409.88 million. Ibio employs 54 workers across the globe.

The official website for Ibio is www.ibioinc.com.

Ibio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650.